-
Posted by
Two Blokes May 16 -
Filed in
Stock
-
2 views
Novo Nordisk (NYSE:NVO) CEO Lars Fruergaard Jørgensen is stepping down after eight years leading the Danish pharmaceutical giant, known for its blockbuster obesity and diabetes drugs Wegovy and Ozempic. The company said on Friday the decision was made by mutual agreement with the company's board amid recent market challenges, including increased competition and a significant decline in the company's share price since mid-2024.
